Jack Keating Joins Implant Sciences` Board of Directors

WILMINGTON, Mass.--(Business Wire)--
Implant Sciences Corporation (OTCBB: IMSC), a supplier of systems and sensors
for the homeland security market and related industries, today announced the
addition of Jack Keating to the Company`s Board of Directors.

Glenn D. Bolduc, Implant Sciences' Chief Executive Officer, commented, "Jack
Keating`s vast experience in global supply chain operations and in all matters
concerning shipping and transportation will be a valuable asset to our Company
as we continue our growth in the transportation security sector. We are
delighted to have him join our Board of Directors."

Mr. Keating commented, "Implant Sciences has an opportunity to use their
proprietary technology to allow global shippers to improve their ability to
safely move cargo around the globe. I am excited to be on the Board and help
this Company realize their potential in this important field."

Mr. Keating, 55, is Vice President of Global Customer Fulfillment for the
Timberland Company, a premium global brand with sales of more than $1.2 billion
in 2008. Mr. Keating has worked for Timberland for 17 years, and is currently
responsible for all of Timberland`s transportation, distribution, customs and
order management. In addition, Mr. Keating oversees Timberland`s North American
customer service and apparel sourcing operations. Mr. Keating has more than 30
years of experience in the shipping and transportation industry, and is a
respected expert in retail distribution and transportation. Mr. Keating holds a
B.A. from Bridgewater State University and an M.B.A. from Suffolk University.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and
systems for the Security, Safety and Defense (SS&D) industries. The Company has
developed proprietary technologies used in its commercial explosive trace
detection systems which ship to a growing number of locations domestically and
internationally. For further details on the Company and its products, please
visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that
term is defined in the Private Securities Litigation Reform Act of 1995. Such
statements are based on management's current expectations and are subject to
risks and uncertainties that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks and uncertainties
include, but are not limited to, the risks that: because the NYSE Amex has
delisted our common stock, it may be extremely difficult to raise capital; if
third party credit is unavailable, our working capital could be restricted and
we may not be able to borrow capital; and other risks and uncertainties
described in the Company's filings with the Securities and Exchange Commission,
including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on
management's current expectations and assumptions which could differ materially
from the forward-looking statements.

Implant Sciences Corporation
Glenn Bolduc, CEO
978 752-1700
gbolduc@implantsciences.com

Copyright Business Wire 2009